Our Pipeline
Our Technology
SENEX is developing metabolic gene therapy to reverse acute or age-driven chronic Inflammatory conditions. Here is how it eliminates the source of chronic inflammation. Stress and ageing lead to buildup of ceramide lipid in cells, which makes cells switch from functional to static (senescent). Senescent cells continuously release pro-inflammatory factors and persistently stimulate immune cells. Over-stimulation of immune system causes tissue damage and functional impairments of the body. SENEX is using a unique adeno-associated virus to deliver a therapeutic gene to the affected tissue. The delivered gene is encoded for Acid Ceramidase, a physiological protein that can stabilize ceramide levels, reverse senescence, and break the cycle of persistent pro-inflammatory stimulation.
Background
SeneX was Founded in 2022, based on gene therapy technology out-licensed from Icahn School of Medicine at Mount Sinai
SeneX has exclusive rights to an entire patent family and the technology is covered by over 20 peer-reviewed studies
SeneX's proprietary agents are focused around a therapeutic gene - called Acid Ceramidase, delivered through a viral vector
Publications
​
1: Acid ceramidase gene therapy ameliorates pulmonary arterial hypertension with right heart dysfunction. Katz MG, Hadas Y, Vincek A, Freage-Kahn L, Shtraizent N, Madjarov JM, Pastuszko P, Eliyahu E. Respir Res. 2023 Aug 11;24(1):197. doi: 10.1186/s12931-023-02487-2. PMID: 37568148; PMCID: PMC10416391.
2: Surgical Methods for Cardiac Gene Delivery in Large Animals. Katz MG, Hadas Y, Vincek AS, Shtraizent N, Gordon HP, Pastuszko P, Schadt E, Eliyahu E. Methods Mol Biol. 2022;2573:189-203. doi: 10.1007/978-1-0716-2707-5_15. PMID: 36040596.
3: Cardiac Targeted Adeno-Associated Virus Injection in Rats. Katz MG, Hadas Y, Vincek AS, Shtraizent N, Schadt E, Eliyahu E. Methods Mol Biol. 2022;2573:135-145. doi: 10.1007/978-1-0716-2707-5_10. PMID: 36040591.
4: Altering Sphingolipid Metabolism Attenuates Cell Death and Inflammatory Response After Myocardial Infarction. Hadas Y, Vincek AS, Youssef E, Żak MM, Chepurko E, Sultana N, Sharkar MTK, Guo N, Komargodski R, Kurian AA, Kaur K, Magadum A, Fargnoli A, Katz MG, Hossain N, Kenigsberg E, Dubois NC, Schadt E, Hajjar R, Eliyahu E, Zangi L. Circulation. 2020 Mar 17;141(11):916-930. doi: 10.1161/CIRCULATIONAHA.119.041882. Epub 2020 Jan 29. PMID: 31992066; PMCID: PMC7135928.
5: Gene therapy targets in postinfarction remodeling. Katz MG, Gubara SM, Eliyahu E. J Thorac Cardiovasc Surg. 2020 May;159(5):e305. doi: 10.1016/j.jtcvs.2019.11.122. Epub 2020 Jan 8. PMID: 31926721.
6: Effects of genetic transfection on calcium cycling pathways mediated by double-stranded adeno-associated virus in postinfarction remodeling. Katz MG, Gubara SM, Hadas Y, Weber T, Kumar A, Eliyahu E, Bridges CR, Fargnoli AS. J Thorac Cardiovasc Surg. 2020 May;159(5):1809-1819.e3. doi: 10.1016/j.jtcvs.2019.08.089. Epub 2019 Sep 30. PMID: 31679707; PMCID: PMC7103560.
7: Acid ceramidase maintains the chondrogenic phenotype of expanded primary chondrocytes and improves the chondrogenic differentiation of bone marrow-derived mesenchymal stem cells. Simonaro CM, Sachot S, Ge Y, He X, Deangelis VA, Eliyahu E, Leong DJ, Sun HB, Mason JB, Haskins ME, Richardson DW, Schuchman EH. PLoS One. 2013 Apr 26;8(4):e62715. doi: 10.1371/journal.pone.0062715. PMID: 23638138; PMCID: PMC3637164.
8: Construction of conditional acid ceramidase knockout mice and in vivo effects on oocyte development and fertility. Eliyahu E, Shtraizent N, Shalgi R, Schuchman EH. Cell Physiol Biochem. 2012;30(3):735-48. doi: 10.1159/000341453. Epub 2012 Aug 1. PMID: 22854249; PMCID: PMC3741991.
9: Acid ceramidase improves the quality of oocytes and embryos and the outcome of in vitro fertilization. Eliyahu E, Shtraizent N, Martinuzzi K, Barritt J, He X, Wei H, Chaubal S, Copperman AB, Schuchman EH. FASEB J. 2010 Apr;24(4):1229-38. doi: 10.1096/fj.09-145508. Epub 2009 Dec 9. PMID: 20007509; PMCID: PMC3231947.
10: Acid ceramidase is a novel factor required for early embryo survival. Eliyahu E, Park JH, Shtraizent N, He X, Schuchman EH. FASEB J. 2007 May;21(7):1403-9. doi: 10.1096/fj.06-7016com. Epub 2007 Jan 30. PMID: 17264167.